Is Magnesium Taurine Cognition Randomized Trial safe?

Updated August 2026

Quick Answer

Magnesium Taurine Cognition Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Additionally, the failure of numerous pharmacological and non-pharmacological single-domain interventions in AD underscores the limitations of targeting single-disease mechanisms or single risk factors.

Key Takeaways

  • 01Additionally, the failure of numerous pharmacological and non-pharmacological single-domain interventions in AD underscores the limitations of targeting single-disease mechanisms or single risk factors. [Bereczki Erika (2025)]
  • 02There is a clear need for strategies addressing multiple risk factors and biological pathways simultaneously, with early intervention in the ADRD continuum being crucial for an optimal preventive effect [,]. [Bereczki Erika (2025)]
  • 03The World Health Organization (WHO) guidelines for risk reduction of cognitive decline and dementia, which are based on the synthesis of findings from intervention trials, recommend, among others, physical activity, a healthy balanced diet, cognitive training, as well as management of hypertension, diabetes, and dyslipidemia, for reducing the risk of cognitive decline []. [Bereczki Erika (2025)]
  • 041 2 3 4 5 6 7 Healthy ageing, preservation of cognitive functioning, and preventing Alzheimer’s disease (AD) and related dementias (ADRD) is a global priority, as effective ADRD therapeutics are still not widely available. [Bereczki Erika (2025)]
The current Migaku evidence database contains 2 reusable source documents for Magnesium Taurine Cognition Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Additionally, the failure of numerous pharmacological and non-pharmacological single-domain interventions in AD underscores the limitations of targeting single-disease mechanisms or single risk factors. [Bereczki Erika (2025); evidence level 1] - There is a clear need for strategies addressing multiple risk factors and biological pathways simultaneously, with early intervention in the ADRD continuum being crucial for an optimal preventive effect [,]. [Bereczki Erika (2025); evidence level 1] - The World Health Organization (WHO) guidelines for risk reduction of cognitive decline and dementia, which are based on the synthesis of findings from intervention trials, recommend, among others, physical activity, a healthy balanced diet, cognitive training, as well as management of hypertension, diabetes, and dyslipidemia, for reducing the risk of cognitive decline []. [Bereczki Erika (2025); evidence level 1] - 1 2 3 4 5 6 7 Healthy ageing, preservation of cognitive functioning, and preventing Alzheimer’s disease (AD) and related dementias (ADRD) is a global priority, as effective ADRD therapeutics are still not widely available. [Bereczki Erika (2025); evidence level 1] - This case series presents outcomes of the first 51 patients who participated in one such program and aims to add to preliminary evidence regarding the efficacy of a personalized multimodal integrative functional medicine approach to cognitive decline in the context of prior uncontrolled and ongoing controlled trials. [Kogan Mikhail (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Risk reduction and precision prevention across the Alzheimer’s disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches
  2. The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series